
About Othram
Othram is a Healthcare company based in Houston (United States) founded in 2018 by David Mittelman. Genomic services are provided for forensic investigations and research. Othram has raised $43.16 million across 7 funding rounds from investors including Illumina and Gigafund. The company has 22 employees. Its chief executive, as recorded, is David Mittelman. Its website othram.com draws about 22 thousand monthly visits. Its focus areas include Life Sciences, Genomics, Applied Genomics and Other Applications. Its legal entity is Othram Inc. Its competitors include DDC Paternity Tests, Applied DNA Sciences and IntegenX; 1 of its 3 listed competitors has raised funding.
Company details
Othram was founded in 2018 and is based in Houston, United States. Operations focus on the genomics sector, where proprietary biomarkers are utilized to analyze genome profiles for forensic and investigative purposes. DNA is recovered from minimal samples through amplification techniques. Solutions are offered for identifying traits such as ancestry lineage, hair color, height, and genetic relatives by comparing genome sequences.
- Headquarters Houston, United States
- Employees 22
- Founders David Mittelman
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website othram.com
- Social LinkedIn X
- Legal Name Othram Inc
- Total Equity Funding$43.16M (USD)
in 7 rounds
- Latest Funding Round$10M (USD), Series B
Sep 2026
- InvestorsIllumina
& 1 more
- Employee Count22
Funding Insights of Othram
Othram has successfully raised a total of $43.16M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $43.16M
- Total Rounds 7
- Last Round Series B β $10M
- First Round $4M
(Mar 2019)
- Investors Count 2
All 7 funding rounds of Othram with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Othram
Othram has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Illumina and Gigafund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in multiple sectors | gigafund.com | Austin, United States | ||
Developer of technologies for analysis of genetic variation and function | 1993 | illumina.com | San Diego, United States |
Investor details for Othram
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Othram
7 people are tracked at Othram (6 in leadership, 1 in team); the tracked headcount is 22.
| Name | Role | Group |
|---|---|---|
David Mittelman | Co-Founder & CEO | Leadership |
Kristen Mittelman | Chief Business Development Officer | Leadership |
Adrian Lopez | Director of Finance | Leadership |
Brendan Belair | Chief Strategy Officer | Leadership |
Colby L. | Chief Of Staff | Leadership |
Lee Baker | Director Of Engineering | Leadership |
Patrick Kinder | General Counsel | Team |
Complete people profiles for Othram
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Othram
3 dated milestones of Othram across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Othram is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Series B, of $10.0M.
Competitors of Othram
Othram has 3 listed competitors in our database, 1 of them funded. They include DDC Paternity Tests, Applied DNA Sciences and IntegenX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dnacenter.com | 1995 | Fairfield, United States | DNA tests and personalized diagnostics are provided for various specialties. | |||
| adnas.com | 1983 | Stony Brook, United States | 55 | Botanical-DNA-based security and authentication solutions are developed. | ||
| integenx.com | 2006 | Pleasanton, United States | $92.06M | 78 | Instruments for rapid human DNA identification are developed. |
Detailed competitors of Othram
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Othram
The website of Othram (othram.com) receives about 22.3K visits a month.
- Monthly visits22.3K
▲ 128% vs previous month
Websites whose visitors overlap most with Othram. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
rcfl.gov | rcfl.gov | 100% | #3,842,205 | β |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Othram (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Othram
Complete news archive for Othram
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Othram
Othram was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Othram is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
David Mittelman is the CEO of Othram, as recorded in our data. They have also founded this company.
Othram is a funded company, having raised a total of $43.16M across 7 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Mar 2019.
Othram has 22 employees.
Othram was founded in 2018 and is based in Houston, United States. Operations focus on the genomics sector, where proprietary biomarkers are utilized to analyze genome profiles for forensic and investigative purposes. DNA is recovered from minimal samples through amplification techniques. Solutions are offered for identifying traits such as ancestry lineage, hair color, height, and genetic relatives by comparing genome sequences.
Othram's top competitors include DDC Paternity Tests, Applied DNA Sciences and IntegenX.
Othram operates through Othram Inc.
